4DMedical’s CT:VQ technology gets thumbs up from TGA.
**Australian Approval for Non-Contrast Ventilation-Perfusion Imaging**
4DMedical Limited, a leader in advanced respiratory imaging, has received approval from the Therapeutic Goods Administration (TGA) in Australia to market its CT:VQ technology. This non-contrast ventilation-perfusion imaging system enables doctors to analyze chest CT scans to detect lung conditions without the need for a contrast agent. CT:VQ is the first and only FDA-cleared product of its kind.
CT:VQ’s innovative approach to lung imaging will significantly benefit patients in Australia. Traditional ventilation-perfusion (V/Q) scans require an injectable contrast agent, which can be costly and expose patients to potential allergies or kidney damage. In contrast, CT:VQ uses advanced algorithms to analyze images from routine chest CT scans, providing a safer and more accessible diagnostic option.
**What this means**
With TGA approval, Australian doctors will now have access to a more efficient and safer way to diagnose lung conditions, such as pulmonary embolism and chronic obstructive pulmonary disease (COPD). This is especially significant for patients undergoing routine chest CT scans, who can now receive a more comprehensive set of diagnostic results without requiring additional contrast agents.
CT:VQ’s technology marks a significant advancement in respiratory imaging and demonstrates 4DMedical’s commitment to developing innovative solutions that improve patient care.
